{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"metastatic castration resistant prostate cancer","name":"PRINCE","nct_id":"NCT03658447","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prince-nct03658447. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PRINCE","arms":[{"description":"200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.","label":"177Lu-PSMA + Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-12-22","type":"ACTUAL"},"conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":{"count":37,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"177Lu-PSMA","otherNames":[],"type":"DRUG"}],"last_update":"2023-07-28","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","official_title":"Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2022-12-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Prostate Specific Antigen (PSA) response","timeFrame":"Through study completion, up until 24 months after the last patient commences treatment."},{"measure":"Incidence of Treatment-Emergent Adverse Events [Safety]","timeFrame":"Through treatment completion, maximum of 24 months"},{"measure":"Tolerability","timeFrame":"Through treatment completion, maximum of 24 months"}],"references":[{"citation":"Sandhu S, Joshua AM, Emmett L, Bressel M, Anton A, Spain L, Horvath LG, Pasam A, Tolmeijer SH, Akhurst TJ, Alipour R, Banks P, Buteau JP, Cassidy E, Crumbaker M, Dhiantravan N, Xu W, Chan J, Hitchen N, Scalzo M, Ravi Kumar AS, Kong G, Wallace R, Williams N, Williams S, Haynes NM, Neeson P, Wyatt AW, Hicks RJ, Hofman MS. [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study. Lancet Oncol. 2026 Apr;27(4):470-479. doi: 10.1016/S1470-2045(26)00017-3.","pmid":"41926961","type":"DERIVED"},{"citation":"Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, McIntosh L, Sandhu S, Hofman MS. Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025 Aug 1;66(8):1265-1270. doi: 10.2967/jnumed.125.269640.","pmid":"40610228","type":"DERIVED"}],"start_date":{"date":"2019-07-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)","url":"https://clinicaltrials.gov/study/NCT03658447"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prince-nct03658447"}